Protalix BioTherapeutics Inc (AMEX:PLX) price closed lower on Monday, June 30, and dropping -3.90% below its previous close.
A look at the daily price movement shows that the last close reads $1.54, with intraday deals fluctuated between $1.43 and $1.6. The company’s 5Y monthly beta was ticking -0.219 while its P/E ratio in the trailing 12-month period read 35.24. Taking into account the 52-week price action we note that the stock hit a 52-week high of $3.10 and 52-week low of $0.82. The stock subtracted -6.92% on its value in the past month.
Protalix BioTherapeutics Inc, which has a market valuation of $117.82 million, is expected to release its quarterly earnings report on 2025-May-09.
Technical indicators in stocks provide crucial insights into market trends, guiding investors with precise entry and exit points based on price movements for informed decision-making.On the technical perspective front, indicators give PLX a short term outlook of 100% Sell on average. Looking at the stock’s medium term indicators we note that it is averaging as a 50% Sell, while an average of long term indicators are currently assigning the stock as 50% Sell.
The overview shows that PLX’s price is at present -1.20% off the SMA20 and -23.87% from the SMA50. The Relative Strength Index (RSI) metric on the 14-day timeframe is pointing at 43.24, with weekly volatility standing at 12.26%. The indicator jumps to 6.76% when calculated based on the past 30 days. Protalix BioTherapeutics Inc (AMEX:PLX)’s beta value is holding at -0.22.
An analysis of the Protalix BioTherapeutics Inc (AMEX:PLX) stock in terms of its daily trading volume indicates that the 3-month average is 1.10 million. However, this figure increases on the past 10-day timeline to an average of 1.93 million.
Current records show that the company has 78.13M in outstanding shares. The insiders’ percentage holdings are 7.28% of outstanding shares while the percentage share held by institutions stands at 11.23%. The stats also highlight that short interest as of 2025-06-13, stood at 1.19 million shares, which puts the short ratio at the time at 1.7. From this we can glean that short interest is 156.00 of company’s current outstanding shares. Notably, we see that shares short in June rose slightly given the previous month’s figure stood at 0.98 million. But the 20.33% upside, the stock’s price has registered year-to-date as of last trading, will likely reignite investor interest given the prospect of it rallying even higher.
